Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Vitamin Market Weakness Paves Way For Acquisitions – NBTY

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

The impact of supplement industry stagnation and negative vitamin E publicity on smaller firms has created new acquisition opportunities for NBTY, President & CFO Harvey Kamil said

You may also be interested in...



NBTY “Tough Quarter” Caused By Vitamin E Sales, Stalled Market - Rudolph

NBTY is predicting a rebound of the current stagnant supplement market as the baby boomer generation continues to enter the "vitamin age.

NBTY “Tough Quarter” Caused By Vitamin E Sales, Stalled Market - Rudolph

NBTY is predicting a rebound of the current stagnant supplement market as the baby boomer generation continues to enter the "vitamin age.

NBTY “Tough Quarter” Caused By Vitamin E Sales, Stalled Market - Rudolph

NBTY is predicting a rebound of the current stagnant supplement market as the baby boomer generation continues to enter the "vitamin age.

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Metsera Launches As New Obesity Contender Flush With $290m

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

See All
UsernamePublicRestriction

Register

PS097910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By